There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS – Research Report) and BioNTech SE (BNTX – Research Report) with bullish sentiments.
COMPASS Pathways (CMPS)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on COMPASS Pathways, with a price target of $120.00. The company’s shares closed last Tuesday at $8.00.
According to TipRanks.com, Trucchio ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on COMPASS Pathways is a Strong Buy with an average price target of $56.00, representing a 612.5% upside. In a report issued on December 11, Deutsche Bank also initiated coverage with a Buy rating on the stock with a $16.00 price target.
See today’s best-performing stocks on TipRanks >>
BioNTech SE (BNTX)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on BioNTech SE, with a price target of $133.00. The company’s shares closed last Tuesday at $106.71.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for BioNTech SE with a $122.08 average price target, implying a 16.8% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $159.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CMPS:
- Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
- These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank
- Rising High: Exclusive talk with cannabis REIT NewLake Capital
- Compass Pathways initiated with bullish view at Deutsche Bank, here’s why
- Here’s What You Missed in Cannabis, Psychedelics This Week
